Richard J Gralla Selected Research

Aprepitant (Emend)

1/2017	Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists.
11/2012	Palliative care: Aprepitant and control of emesis induced by 5-day chemotherapy.
3/2011	Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only).
11/2010	Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients.
6/2006	American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.
8/2005	Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
6/2005	The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
4/2005	Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
11/2003	The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
5/2003	Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard J Gralla Research Topics

Disease

25	Vomiting 01/2020 - 02/2002
19	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/2019 - 02/2004
17	Nausea 01/2020 - 10/2002
10	Neoplasms (Cancer) 02/2018 - 05/2003
7	Lung Neoplasms (Lung Cancer) 01/2017 - 01/2004
3	Breast Neoplasms (Breast Cancer) 01/2020 - 04/2005
3	Disease Progression 01/2017 - 05/2013
2	Neutropenia 06/2016 - 04/2016
2	Weight Loss (Weight Reduction) 01/2016 - 12/2004
2	Infections 02/2008 - 05/2003
2	Malignant Mesothelioma 01/2006 - 08/2004
2	Pain (Aches) 12/2004 - 02/2004
2	Fatigue 02/2004 - 01/2004
1	Anaphylaxis (Anaphylactic Shock) 01/2020
1	Hypersensitivity (Allergy) 01/2020
1	Inappropriate ADH Syndrome (SIADH) 04/2017
1	Hyponatremia 04/2017
1	Diarrhea 01/2017
1	Exanthema (Rash) 01/2017
1	Thrombocytopenia (Thrombopenia) 06/2016
1	Alopecia (Baldness) 04/2016
1	Anemia 01/2014
1	Hemorrhage 01/2014
1	Carcinogenesis 05/2013
1	Pulmonary Embolism 11/2012
1	Thrombosis (Thrombus) 11/2012
1	Venous Thrombosis (Deep-Vein Thrombosis) 11/2012
1	Venous Thromboembolism 11/2012
1	Interstitial Lung Diseases (Interstitial Lung Disease) 06/2009
1	Mesothelioma 01/2006
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2004
1	Dyspnea (Shortness of Breath) 01/2004

Drug/Important Bio-Agent (IBA)

10	Aprepitant (Emend)FDA Link 01/2017 - 05/2003
9	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020 - 01/2004
9	AntiemeticsIBA 01/2020 - 10/2002
8	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 05/2003
7	Docetaxel (Taxotere)FDA Link 10/2018 - 02/2004
6	AnthracyclinesIBA 01/2020 - 11/2010
6	Palonosetron (Aloxi)FDA Link 01/2017 - 04/2006
5	Dexamethasone (Maxidex)FDA LinkGeneric 01/2017 - 05/2003
4	Ondansetron (Zofran)FDA LinkGeneric 01/2017 - 05/2003
4	Granisetron (Kytril)FDA LinkGeneric 01/2017 - 04/2006
4	PlatinumIBA 01/2013 - 02/2004
3	ErbB Receptors (EGF Receptor)IBA 01/2017 - 05/2013
3	Tyrosine Kinase InhibitorsIBA 01/2017 - 06/2015
3	Gemcitabine FDA Link 06/2016 - 01/2008
3	5-HT3 Serotonin Receptors (5 HT3 Receptor)IBA 04/2016 - 05/2003
3	Pemetrexed (MTA)FDA Link 01/2008 - 08/2004
2	NivolumabIBA 10/2018 - 01/2018
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2017 - 01/2017
2	Pharmaceutical PreparationsIBA 01/2017 - 11/2010
2	Gefitinib (Iressa)FDA Link 01/2017 - 01/2017
2	Vinorelbine (Navelbine)FDA LinkGeneric 01/2007 - 12/2004
2	EmeticsIBA 06/2006 - 06/2005
2	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2005 - 01/2004
1	fosaprepitant FDA Link 01/2020
1	serum P-component (CIt)IBA 07/2019
1	SaltsIBA 04/2017
1	ElectrolytesIBA 04/2017
1	SodiumIBA 04/2017
1	Tolvaptan FDA Link 04/2017
1	Vasopressins (Vasopressin)IBA 04/2017
1	AfatinibIBA 01/2017
1	Antineoplastic Agents (Antineoplastics)IBA 01/2017
1	Olanzapine (Zyprexa)FDA Link 01/2017
1	Metoclopramide (Reglan)FDA LinkGeneric 01/2017
1	rolapitantIBA 01/2017
1	necitumumabIBA 06/2016
1	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2016
1	Neurokinin-1 Receptor AntagonistsIBA 04/2016
1	ostarineIBA 01/2016
1	Androgen Receptors (Androgen Receptor)IBA 01/2016
1	Delayed-Action PreparationsIBA 03/2015
1	SteroidsIBA 01/2014
1	Factor VIII (Coagulation Factor VIII)IBA 01/2014
1	Rituximab (Mabthera)FDA Link 01/2014
1	von Willebrand FactorIBA 01/2014
1	Fondaparinux (Arixtra)FDA Link 11/2012
1	Factor Xa InhibitorsIBA 11/2012
1	Paclitaxel (Taxol)FDA LinkGeneric 06/2009
1	Anti-Bacterial Agents (Antibiotics)IBA 02/2008
1	Serotonin AntagonistsIBA 06/2006
1	Drug CombinationsIBA 06/2006
1	Substance PIBA 04/2006
1	casopitantIBA 04/2006
1	Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA 04/2006
1	netupitantIBA 04/2006
1	dolasetron (Anzemet)FDA Link 04/2006
1	Tropisetron (Navoban)IBA 04/2006
1	vestipitantIBA 04/2006
1	Epirubicin (Ellence)FDA LinkGeneric 04/2005

Therapy/Procedure

30	Drug Therapy (Chemotherapy) 01/2020 - 10/2002
16	Therapeutics 02/2018 - 02/2002
2	Radiotherapy 10/2018 - 03/2011
2	Neoadjuvant Therapy 03/2009 - 01/2008
2	Combination Drug Therapy (Combination Chemotherapy) 01/2007 - 11/2004
1	Aftercare (After-Treatment) 06/2015
1	Palliative Care (Palliative Therapy) 11/2012
1	Vena Cava Filters (Inferior Vena Cava Filter) 11/2012
1	Adjuvant Chemotherapy 01/2009